Skip to content

Educational reference only. Not medical advice. Nothing on this site is for sale.

October 28, 2026CompoundingHHS lets 503A pharmacies compound six peptides under an interim enforcement discretion policyOctober 28, 2026Trial resultRetatrutide beats Ozempic on blood sugar and weight in head-to-head TRANSCEND-T2D-2 trialOctober 23, 2026FDA approvalFDA extends once-weekly insulin icodec (Awiqli) to children 10 and older with type 2 diabetesOctober 21, 2026CompoundingCitizen petition asks FDA not to allow compounding of seven peptides reviewed by its advisory committeeOctober 1, 2026Trial resultSurvodutide SYNCHRONIZE-2 phase 3 results in obesity with type 2 diabetes published in NEJMSeptember 30, 2026Trial resultEloraTZP (eloralintide plus tirzepatide) phase 2 results presented at EASD 2026September 30, 2026Trial resultOrforglipron ACHIEVE-4 cardiovascular safety trial published in The LancetSeptember 29, 2026Trial resultFull TRIUMPH-2 retatrutide results published in The LancetSeptember 24, 2026FDA approvalFDA approves insulin efsitora alfa (Onswik), a once-weekly basal insulin for type 2 diabetesSeptember 21, 2026WADAWADA publishes 2027 Prohibited List, naming peptides as examples of non-approved substances

October 28, 2026CompoundingHHS lets 503A pharmacies compound six peptides under an interim enforcement discretion policyOctober 28, 2026Trial resultRetatrutide beats Ozempic on blood sugar and weight in head-to-head TRANSCEND-T2D-2 trialOctober 23, 2026FDA approvalFDA extends once-weekly insulin icodec (Awiqli) to children 10 and older with type 2 diabetesOctober 21, 2026CompoundingCitizen petition asks FDA not to allow compounding of seven peptides reviewed by its advisory committeeOctober 1, 2026Trial resultSurvodutide SYNCHRONIZE-2 phase 3 results in obesity with type 2 diabetes published in NEJMSeptember 30, 2026Trial resultEloraTZP (eloralintide plus tirzepatide) phase 2 results presented at EASD 2026September 30, 2026Trial resultOrforglipron ACHIEVE-4 cardiovascular safety trial published in The LancetSeptember 29, 2026Trial resultFull TRIUMPH-2 retatrutide results published in The LancetSeptember 24, 2026FDA approvalFDA approves insulin efsitora alfa (Onswik), a once-weekly basal insulin for type 2 diabetesSeptember 21, 2026WADAWADA publishes 2027 Prohibited List, naming peptides as examples of non-approved substances

Peptide CompendiumLanguageSign in

Pre-mixed blend

AOD-9604 + CJC-1295 + Ipamorelin

A seller-made three-peptide mix promoted for fat loss.

What is in it

Metabolic & weightEarly human dataFlashcard

AOD-9604

AOD9604 · Tyr-hGH 177-191

AOD-9604 is a small piece of human growth hormone that was developed in Australia as a fat-loss drug.

Growth hormone axisEarly human dataFlashcard

CJC-1295

CJC-1295 with DAC · CJC-1295 without DAC

CJC-1295 is a lab-made, modified version of the active part of growth-hormone-releasing hormone.

Growth hormone axisEarly human dataFlashcard

Ipamorelin

Ipamorelin acetate · NNC 26-0161

Ipamorelin is a small lab-made peptide (five building blocks) that copies the hunger hormone ghrelin to make the pituitary release growth hormone.

Is there evidence for the combination?

We found no published study of this mix. AOD-9604 failed to beat placebo for weight loss in its own human trials. See its page.

Each ingredient at a glance

Ingredient	Evidence	US FDA status	Sports (WADA)
AOD-9604	Early human data	Not FDA-approved for any use.	Prohibited at all times: listed by name under S2.2.3 (growth hormone…
CJC-1295	Early human data	Not FDA-approved; development discontinued	Prohibited at all times (S2.2.4 GHRH and analogues; CJC-1295 named)
Ipamorelin	Early human data	Not FDA-approved	Prohibited at all times (S2.2.4 growth hormone secretagogues; named)

Mixing adds unknowns. A blend carries the risks of every ingredient, and the interactions are untested. Vial contents and ratios are set by sellers and are not standardized. See each ingredient page for safety and legal details.